CY1125033T1 - Σκευασμα μεθοτρεξατης - Google Patents

Σκευασμα μεθοτρεξατης

Info

Publication number
CY1125033T1
CY1125033T1 CY20221100172T CY221100172T CY1125033T1 CY 1125033 T1 CY1125033 T1 CY 1125033T1 CY 20221100172 T CY20221100172 T CY 20221100172T CY 221100172 T CY221100172 T CY 221100172T CY 1125033 T1 CY1125033 T1 CY 1125033T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
methotrexate
preparation
methotrexate preparation
Prior art date
Application number
CY20221100172T
Other languages
English (en)
Inventor
Michael FRODSHAM
Julie-Ann PENTON
Original Assignee
Therakind Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakind Ltd. filed Critical Therakind Ltd.
Publication of CY1125033T1 publication Critical patent/CY1125033T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Υγρή φαρμακευτική σύνθεση περιλαμβάνει ελεύθερο οξύ μεθοτρεξάτης και ρυθμιστικό διάλυμα, όπου το pΗ της σύνθεσης είναι της τάξεως του 6,5 έως 8,2. Περιγράφονται επίσης μέθοδοι για την παρασκευή της υγρής φαρμακευτικής σύνθεσης. Η υγρή φαρμακευτική σύνθεση είναι χρήσιμη σε θεραπεία.
CY20221100172T 2014-10-29 2022-03-01 Σκευασμα μεθοτρεξατης CY1125033T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1419261.1A GB201419261D0 (en) 2014-10-29 2014-10-29 Formulations
PCT/GB2015/053231 WO2016067024A1 (en) 2014-10-29 2015-10-28 Methotrexate formulation

Publications (1)

Publication Number Publication Date
CY1125033T1 true CY1125033T1 (el) 2023-03-24

Family

ID=52103589

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100172T CY1125033T1 (el) 2014-10-29 2022-03-01 Σκευασμα μεθοτρεξατης

Country Status (20)

Country Link
US (3) US11129833B2 (el)
EP (1) EP3212237B1 (el)
JP (3) JP2017533274A (el)
CN (2) CN116747190A (el)
AU (1) AU2015340373A1 (el)
CA (1) CA3002493C (el)
CY (1) CY1125033T1 (el)
DK (1) DK3212237T3 (el)
ES (1) ES2908447T3 (el)
GB (2) GB201419261D0 (el)
HK (1) HK1243638A1 (el)
HR (1) HRP20220105T1 (el)
HU (1) HUE057717T2 (el)
IL (1) IL251859A0 (el)
LT (1) LT3212237T (el)
PL (1) PL3212237T3 (el)
PT (1) PT3212237T (el)
RS (1) RS62971B1 (el)
SI (1) SI3212237T1 (el)
WO (1) WO2016067024A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN107714653B (zh) * 2017-11-27 2022-01-28 济南新科医药科技有限公司 一种稳定的可溶性甲氨蝶呤颗粒剂
WO2019162756A2 (en) * 2018-02-20 2019-08-29 Ftf Pharma Private Limited Liquid pharmaceutical compositions of anticancer drugs
GB2591681A (en) * 2018-08-29 2021-08-04 Ftf Pharma Private Ltd Methotrexate pharmaceutical composition
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
WO2023009228A1 (en) * 2021-07-30 2023-02-02 Epygenix Therapeutics, Inc. Clemizole formulation
CN115778897A (zh) * 2022-12-15 2023-03-14 深圳市贝美药业有限公司 一种稳定的甲氨蝶呤药物制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US101605A (en) * 1870-04-05 Gael fogelberg
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5593671A (en) * 1994-07-01 1997-01-14 American Cyanamid Company Method of attenuating lung capillary leak in a mammal
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2003007961A1 (en) 2001-07-20 2003-01-30 Iomed, Inc. Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments
US20050101605A1 (en) 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
WO2010070705A1 (ja) * 2008-12-17 2010-06-24 株式会社メドレックス アムロジピンの安定な含水経口製剤
KR101779214B1 (ko) * 2009-04-24 2017-09-18 하. 룬드벡 아크티에셀스카브 １―［２―（２，４―디메틸페닐술파닐）페닐］피페라진 염의 액체 제형
GB201200192D0 (en) * 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
JPWO2015147018A1 (ja) * 2014-03-28 2017-04-13 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations

Also Published As

Publication number Publication date
EP3212237A1 (en) 2017-09-06
US20170312281A1 (en) 2017-11-02
PL3212237T3 (pl) 2022-04-19
GB2531940A (en) 2016-05-04
CN116747190A (zh) 2023-09-15
HUE057717T2 (hu) 2022-06-28
CA3002493C (en) 2023-11-28
PT3212237T (pt) 2022-04-14
DK3212237T3 (da) 2022-03-07
CA3002493A1 (en) 2016-05-06
SI3212237T1 (sl) 2022-04-29
CN107106485A (zh) 2017-08-29
US20240024327A1 (en) 2024-01-25
RS62971B1 (sr) 2022-03-31
EP3212237B1 (en) 2022-01-05
US11129833B2 (en) 2021-09-28
LT3212237T (lt) 2022-02-25
JP2023103402A (ja) 2023-07-26
JP2017533274A (ja) 2017-11-09
US20210386746A1 (en) 2021-12-16
HRP20220105T1 (hr) 2022-04-15
GB2531940B (en) 2017-04-26
AU2015340373A1 (en) 2017-05-18
WO2016067024A1 (en) 2016-05-06
JP2021138748A (ja) 2021-09-16
HK1243638A1 (zh) 2018-07-20
US11771701B2 (en) 2023-10-03
IL251859A0 (en) 2017-06-29
GB201519049D0 (en) 2015-12-09
GB201419261D0 (en) 2014-12-10
ES2908447T3 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1121736T1 (el) Άλατα aramchol
CY1124076T1 (el) Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου